Goldman Sachs analyst Neil Mehta raised the firm’s price target on Calumet (CLMT) to $34 from $24 and keeps a Buy rating on the shares. Estimates across U.S. Majors and Canadian Oils have been updated to reflect recent Middle East disruptions, with price targets raised despite strong year-to-date equity performance, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CLMT:
- Calumet Specialty Products Balances Big Gains and Headwinds
- Calumet price target raised to $25 from $19 at TD Cowen
- Calumet: Improved Core Performance but SAF Market and Regulatory Uncertainty Justify Hold Rating
- Calumet reports Q4 EPS (43c), consensus (46c)
- CLMT Earnings this Week: How Will it Perform?